Fibroblast Growth Factor-19 Levels in Type 2 Diabetic Patients with Metabolic Syndrome

Basit Öğe Kaydı
dc.contributor.authorBarutcuoglu, Burcu
dc.contributor.authorBasol, Gunes
dc.contributor.authorCakir, Yasemin
dc.contributor.authorCetinkalp, Sevki
dc.contributor.authorParildar, Zuhal
dc.contributor.authorKabaroglu, Ceyda
dc.contributor.authorOzmen, Dilek
dc.contributor.authorMutaf, Isil
dc.contributor.authorBayindir, Oya
dc.date.accessioned2019-10-27T21:36:45Z
dc.date.available2019-10-27T21:36:45Z
dc.date.issued2011
dc.departmentEge Üniversitesien_US
dc.description.abstractThis study aimed to examine fibroblast growth factor-19 (FGF-19) in type 2 diabetic (T2DM) patients with metabolic syndrome (MetS) and to evaluate the relationship between FGF-19 and other cardiovascular risk factors, such as atherogenic index of plasma (AIP) and hsCRP. 26 T2DM patients with MetS and 12 healthy controls were enrolled in the study. Serum FGF-19 levels were measured by sandwich ELISA, and compared with other cardiovascular risk factors; lipid profile, AIP, glucose, HbA1c, and hsCRP. AIP was calculated as log (TG/HDL-c). The median (1-3.quartile) FGF-19 levels in T2DM patients with MetS and healthy controls were 122.90 (108.63-237.60) pg/ml and 293.45 (153.64-370.31) pg/ml, respectively (P=0.003). Patients were also grouped by body mass index (BMI) <30 kg/m(2) (n=13) and >= 30 kg/m(2) (n=13) with median (1-3.quartile) FGF-19 values 168.70 (113.54-275.77) pg/mL and 115.89 (97.94-200.40) pg/mL, respectively (P=0.007). Significant negative correlations were found between FGF-19 and BMI, triglyceride, log (TG/HDL-c), hsCRP, and HbA1c (r=-0.526, P=0.001; r=-0.327, P=0.05; r=-0.312, P=0.05; r=-0.435, P=0.006; r=-0.357, P=0.028, respectively). We showed that FGF-19 levels are low in T2DM patients with MerS. The negative relationship between FGF-19 and several known cardiovascular risk factors such as TG, log (TG/HDL-c), hsCRP and HbA1c in diabetic patients with MetS suggests that FGF-19 can be used as a contributing marker.en_US
dc.identifier.endpage396en_US
dc.identifier.issn0091-7370
dc.identifier.issn1550-8080
dc.identifier.issue4en_US
dc.identifier.pmid22166511en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage390en_US
dc.identifier.urihttps://hdl.handle.net/11454/46110
dc.identifier.volume41en_US
dc.identifier.wosWOS:000298822100014en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAssoc Clinical Scientistsen_US
dc.relation.ispartofAnnals of Clinical and Laboratory Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectfibroblast growth factor-19en_US
dc.subjecttype 2 diabetes mellitusen_US
dc.subjectmetabolic syndromeen_US
dc.subjectcardiovascular risk factoren_US
dc.titleFibroblast Growth Factor-19 Levels in Type 2 Diabetic Patients with Metabolic Syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu